Table 2.
The characterization of breast cancer patients involved into the study.
| Clinical characteristic | Breast cancer (n = 74) |
|---|---|
| Age | 55 ± 10 years |
| > 50 years | 46 (62%) |
| < 50 years | 26 (35%) |
| No data | 2 (3%) |
| BMI | Average 27,7 |
| Normal (BMI 18,5–24,99) | 21 (28%) |
| Overweight (25–29,99) | 27 (36%) |
| Obese class I (30–34,99) | 13 (18%) |
| Obese class II (35–39,99) | 5 (7%) |
| Obese class III (> 40) | 1 (1%) |
| No data | 7 (10%) |
| Histopathological result | |
| NST invasive cancer | 64 (86%) |
| Sarkoid carcinoma | 1 (1%) |
| Invasive lobular carcinoma | 3 (4%) |
| Preinvasive ductal carcinoma | 1 (1%) |
| Mucous carcinoma | 1 (1%) |
| NST invasive cancer with preinvasive ductal carcinoma | 1 (1%) |
| NST invasive cancer with mucous cancer | 1 (1%) |
| No data | 2 (3%) |
| Size of primary tumor (TNM) | |
| T1 | 5 (7%) |
| T2 | 42 (57%) |
| T3 | 6 (8%) |
| T4 | 17 (23%) |
| No data | 4 (5%) |
| Degree of spread to regional lymph nodes (TNM) | |
| N0 | 29 (39%) |
| N1 | 30 (41%) |
| N2 | 10 (14%) |
| N3 | 1 (1%) |
| No data | 4 (5%) |
| Clinical stage | |
| I | 2 (3%) |
| II | 43 (58%) |
| III | 25 (34%) |
| No data | 4 (5%) |
| Molecular/ biological type | |
| Luminal A (HER2(-), ER/PR( +)) | 6 (8%) |
| Luminal B (HER( +), ER/PR( +)) | 42 (57%) |
| Non-luminal (HER2( +), ER/PR(-)) | 18 (24%) |
| Triple negative (HER2(-), ER/PR(-)) | 6 (8%) |
| No data | 2 (3%) |
| Degree of remission | |
| Partial remission | 30 (41%) |
| Entire remission | 31 (42%) |
| Patients during treatment | 13 (18%) |